Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hezhong Yan"'
Autor:
Xing He, Hezhong Yan, Jie Hu, Xiaowei Duan, Mingjin Zhang, Haiqing Li, Jiaoxue Wang, Qian Gao, Senyuan Yu, Xilu Hou, Guobin Liao, Shicun Guo, Jin Li, Yurong Ge, Xiaolan Chen, Wenchao Wang, Jun Tang
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
ObjectiveTo analyze and evaluate the role of the High-throughput Drug Sensitivity (HDS) screening strategy in identifying highly sensitive drugs against esophageal squamous cell carcinoma (ESCC).MethodsA total of 80 patients with progressive ESCC wer
Externí odkaz:
https://doaj.org/article/838fe524021c42f2896dc9818eb10ce1
Autor:
Xiaowei Duan, Xing He, Hezhong Yan, Haiqing Li, Jiaoxue Wang, Shicun Guo, Zhengwei Zha, Qianqian Zhang, Yuchuan Bai, Jiayi Zhang, Jun Tang, Derun Kong
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 2023 (2023)
Objective. To identify any concomitant complications other than bleeding (COTB) before and after endoscopic treatment of esophagogastric variceal bleeding (EGVB) in liver cirrhosis patients and explore the underlying risk factors. Materials and Metho
Externí odkaz:
https://doaj.org/article/cadbc964e9434e05a6891d41ab5eed08
Autor:
Shuang Qi, Feiyang Liu, Zongru Jiang, Wu Hong, Hezhong Yan, Cheng Chen, Jing Liu, Jun Tang, Qingsong Liu, Chen Hu, Ziping Qi, Wenchao Wang, Beilei Wang, Tingting Lu, Li Wang, Zhenquan Hu, Aoli Wang, Wenliang Wang, Jiaxin Wu, Mingfeng Bai
Publikováno v:
Cancer letters. 447
Despite of the great success of imatinib as the first-line treatment for GISTs, the majority of patients will develop drug-acquired resistance due to secondary mutations in the cKIT kinase. Sunitinib and regorafenib have been approved as the second a
Autor:
Aoli Wang, Xiaochuan Liu, Fengming Zou, Jun Tang, Jiaxin Wu, Juan Ge, Jing Liu, Ziping Qi, Cheng Chen, Hezhong Yan, Kailin Yu, Zongru Jiang, Qingsong Liu, Wenliang Wang, Xue-Song Liu, Jiao-Xue Wang, Beilei Wang, Li Wang, Chen Hu, Wenchao Wang, Tao Ren
Publikováno v:
Oncotarget
KIT kinase V559D mutation is the most prevalent primary gain-of-function mutation in Gastrointestinal Stromal Tumors (GISTs). Here we reported a highly selective KIT V559D inhibitor CHMFL-KIT-031, which displayed about 10-20 fold selectivity over KIT
FPR2 promotes invasion and metastasis of gastric cancer cells and predicts the prognosis of patients
Autor:
Jiao-Xue Wang, Wei Liu, Ji-Ming Wang, Yan Wang, Peng Zhang, Xiu-Wu Bian, Yan-Xia Wang, Dongfang Xiang, Jun Tang, Hezhong Yan, Hai-Qing Li, You-Hong Cui, Cheng-Dong Ji, Weiwei Liu, Xi-Lu Hou
Publikováno v:
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Formyl peptide receptor 2 (FPR2), a classical chemoattractant receptor of G-protein-coupled receptors, is reported to be involved in invasion and metastasis of some cancers, but the role of FPR2 in gastric cancer (GC) has not yet been elucidated. In